Brief: Erytech And Pherecydes Announce Proposed Combination Intending To Create Global Leader In Extended Phage Therapies
15/02/2023 21:39
Feb 15 (Reuters) - Erytech Pharma Sa ERYP.PA :
* ERYTECH AND PHERECYDES ANNOUNCE PROPOSED COMBINATION
INTENDING
TO CREATE GLOBAL LEADER IN EXTENDED PHAGE THERAPIES
* ERYTECH PHARMA - COMBINED CO CASH RUNWAY WOULD EXTEND INTO
Q3
2024, WITH CONSOLIDATED CASH POSITION OF ABOUT €41 MILLION AS OF
DECEMBER 31, 2022
* ERYTECH PHARMA - TRANSACTION EXPECTED TO CLOSE AT THE END
OF THE
SECOND QUARTER OF 2023
* ERYTECH PHARMA - THIBAUT DU FAYET, CURRENTLY CEO OF
PHERECYDES,
WILL BECOME CEO OF ERYTECH
* ERYTECH PHARMA - UPON COMPLETION OF TRANSACTION PHERECYDES
SHAREHOLDERS ARE EXPECTED TO HOLD ABOUT 49.5% OF SHARE CAPITAL
AND VOTING RIGHTS OF ERYTECH
* MR. ERIC SOYER WILL REMAIN COO AND CFO OF ERYTECH
Source text for Eikon: ID:nGNE808vkn
Further company coverage: ERYP.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pherecydes Pharma SA
See all newsBrief: Erytech And Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
Brief: Pherecydes Pharma SA - Pherecydes Pharma And Erytech Pharma Shareholders Approve Merger Between Two Companies To Create Phaxiam Therapeutics
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes